{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"afutuzumab"},{"type":"Synonym","name":"anti-CD20 monoclonal antibody R7159"},{"type":"CodeName","name":"GA101"},{"type":"CodeName","name":"GA-101"},{"type":"CodeName","name":"R7159"},{"type":"USBrandName","name":"Gazyva"},{"type":"CASRegistryName","name":"949142-50-1"},{"type":"Synonym","name":"huMAB(CD20)"},{"type":"CodeName","name":"RO 5072759"},{"type":"CodeName","name":"RO-5072759"},{"type":"CodeName","name":"RO5072759"}],"definition":{"html":"A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.","text":"A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/obinutuzumab","text":"Obinutuzumab"},"nciConceptId":"C70741","nciConceptName":"Obinutuzumab","termId":570643,"name":"obinutuzumab","firstLetter":"o","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"obinutuzumab"}],"links":null}